Telaprevir

Type: Keyphrase
Name: Telaprevir
First reported Oct 31 2014 - Updated 20 hours ago - 1 reports

Market Update (NASDAQ:VRTX): Vertex to Present at the Credit Suisse Healthcare Conference on November 11

[Business Wire] – Vertex Pharmaceuticals Incorporated today announced that it will present at the Credit Suisse Healthcare Conference on Tuesday, November 11 at 12:00 p.m. ET.Read more on this.Vertex Pharmaceuticals Incorporated (VRTX) , currently valued ... [Published Jutia Group - Oct 31 2014]
First reported Oct 29 2014 - Updated Oct 29 2014 - 1 reports

Pros and Cons of New Hepatitis C Treatments for Patients

Hepatitis C treatment has been getting faster, simpler, and more effective.Patients on the newest hepatitis C medication, Harvoni, need only pop one pill per day. Some can be cured in as little as eight weeks. This is a huge difference from just a few ... [Published EverydayHealth.com - Oct 29 2014]
First reported Oct 28 2014 - Updated Oct 28 2014 - 1 reports

How Valuable Is It to Cure a Disease?

• 10:00 AMIllustration of the hepatitis virus. (Photo: xrender/Shutterstock)It depends on the disease—for some, breast cancer and AIDS for example, non-curative therapy that can extend life a little or a lot is considered invaluable. For hepatitis C, ... [Published Pacific Standard - Oct 28 2014]
First reported Oct 24 2014 - Updated Oct 24 2014 - 1 reports

The Price of Progress in Hepatitis C Management

The hepatitis C virus is the most common blood-borne pathogen in the United States, with which more than 3 million people are currently infected.1 Complications of chronic viral hepatitis C infection—including cirrhosis, end-stage liver disease, hepatocellular ... [Published American Journal of Managed Care - Oct 24 2014]
First reported Oct 24 2014 - Updated Oct 24 2014 - 1 reports

Individualized Treatment of Genotype 1 Naïve Patients: An Italian Multicenter Field Practice Experience

by Alessandra Mangia, Giovanni Cenderello, Alessandra Orlandini, Valeria Piazzolla, Antonio Picciotto, Massimo Zuin, Alessia Ciancio, Giuseppina Brancaccio, Paolo Forte, Vito Carretta, Anna Linda Zignego, Nicola Minerva, Gaetano Brindicci, Massimo Marignani, ... [Published Plosone.org - Oct 24 2014]
First reported Oct 10 2014 - Updated Oct 10 2014 - 3 reports

Janssen demonstrates continued commitment to combating Hepatitis C in European patients with data presented at Viral Hepatitis Congress

(Janssen) today announced the presentation of additional data for the NS3/4A protease inhibitor OLYSIO® (simeprevir) at the Viral Hepatitis Congress (VHC) in Frankfurt, Germany. The data includes new analysis of a European and Israeli Hepatitis C (HCV) ... [Published European Pharmaceutical Review - Oct 10 2014]
First reported Oct 07 2014 - Updated Oct 07 2014 - 1 reports

Literatus: Updates on HCV

ONE advantage in using the medical lingo is the shorter word or phrase that provides info, compared to using conversational terms. The disadvantage: readers may not understand it. However, when do we start doing this, even a little each week? The favorite ... [Published Sun Star Network - Oct 07 2014]
First reported Sep 30 2014 - Updated Sep 30 2014 - 2 reports

Chronic Hepatitis C

Section Sponsored by:Chronic hepatitis C virus (HCV) infection is becoming the fastest growing cause of cancer-related death and the leading cause of liver transplantation among adults in the United States. 1 Experts estimate that between 1990 and 2015 ... [Published Advance for NPs and PAs - Sep 30 2014]
First reported Sep 26 2014 - Updated Sep 26 2014 - 2 reports

Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update, New Report Launched

Lewes, DE -- (SBWIRE) -- 09/26/2014 -- PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update report Provide Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute ... [Published Reliance Trust - Sep 26 2014]
First reported Sep 26 2014 - Updated Sep 26 2014 - 1 reports

Triple Therapy for Chronic HCV

Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29(Suppl 1): 74–81.Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med ... [Published General Medicine eJournal - Sep 26 2014]
First reported Sep 23 2014 - Updated Sep 24 2014 - 2 reports

Management of Hepatitis C Genotype 1 Monoinfection

Makia Dove, PharmD Candidate, Clarice Carthon, PharmD Candidate, Monika N. Daftary, PharmD, BCPS, AAHIVPDisclosuresUS Pharmacist. 2014;39(4):75-79.Abstract and Introduction AbstractHepatitis C is a common cause of end-stage liver disease in the United ... [Published General Medicine eJournal - Sep 24 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 2 reports

The Hepatitis C virus is the main cause of liver transplant in the world

/PRNewswire/ -- The Chemistry, Food & Drugs Division of the Trinidad & Tobago Ministry of Health approved the introduction of Telaprevir to the market, an innovative therapy that significantly increases the cure rate from Hepatitis C, and it is indicated ... [Published BioPortfolio - Jul 25 2014]

Quotes

...By tracking the size and price of each montha'a "s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin."
The following quote was obtained by the news editors from the background information supplied by the inventors: "The HCV is an RNA virus belonging to the Hepacivirus genus in the Flaviviridae family. The enveloped HCV virion contains a positive stranded RNA genome encoding all known virus-specific proteins in a single, uninterrupted, open reading frame. The openopen reading frame comprises approximately 9500 nucleotides and encodes a single large polyprotein of about 3000 amino acids. The polyprotein comprises a core protein, envelope proteins E1 and E2, a membrane bound protein p7, and the non-structural proteins NS2, NS3, NS4A, NS4B, NS5A and NS5B."

More Content

All (41) | News (34) | Reports (0) | Blogs (6) | Audio/Video (0) | Fact Sheets (1) | Press Releases (0)
sort by: Date | Relevance
Visterra Announces Additions to Its Management ... [Published Franklin Credit Management Corporation - Oct 31 2014]
Market Update (NASDAQ:VRTX): Vertex to Present ... [Published Jutia Group - Oct 31 2014]
Identification of a Novel Drug Lead That Inhibi... [Published Plosone.org - Oct 30 2014]
Liver Transplant Recipients With Recurrent HCV ... [Published General Medicine eJournal - Oct 30 2014]
Pros and Cons of New Hepatitis C Treatments for... [Published EverydayHealth.com - Oct 29 2014]
How Valuable Is It to Cure a Disease? [Published Pacific Standard - Oct 28 2014]
BOOM, VRTX, HIW, X, EQR, FISV Expected To Be Do... [Published Individual.com - Oct 27 2014]
The Price of Progress in Hepatitis C Management [Published American Journal of Managed Care - Oct 24 2014]
Individualized Treatment of Genotype 1 Naïve Pa... [Published Plosone.org - Oct 24 2014]
Second Wave Anti-HCV Protease Inhibitors [Published General Medicine eJournal - Oct 17 2014]
New hepatitis C hopes [Published Australian Doctor - Oct 16 2014]
New Treatments for Hepatitis C [Published MedIndia - Oct 13 2014]
Janssen demonstrates continued commitment to co... [Published European Pharmaceutical Review - Oct 10 2014]
"Methods for Treating Hcv" in Patent Applicatio... [Published Pharmacy Choice - Oct 10 2014]
Janssen Demonstrates Continued Commitment to Co... [Published CNBC - Oct 10 2014]
Janssen Demonstrates Continued Commitment to -2- [Published Scottrade - Oct 10 2014]
HCV market forecast to total US$12.8Bn by 2022 [Published Live-PR.com - Oct 07 2014]
Literatus: Updates on HCV [Published Sun Star Network - Oct 07 2014]
Sovaldi ‘unaffordable’ says NHS documents [Published Pharmafocus - Oct 07 2014]
Chronic Hepatitis C [Published Advance for NPs and PAs - Sep 30 2014]
20 years since interferon was listed on the PBS... [Published Medianet - Sep 30 2014]
Opinion/decision on a Paediatric Investigation ... [Published Opinion/decision on a Paediatric Investigation ... - Sep 29 2014]
Global Sales of Hepatitis C Virus Market to Gro... [Published PRWeb - Sep 28 2014]
Hepatitis C Virus - Global Drug Forecast and Ma... [Published Reliance Trust - Sep 26 2014]
Global Hepatitis C Virus Drug Industry to 2022 [Published MyNewsDesk - Sep 26 2014]
Triple Therapy for Chronic HCV [Published General Medicine eJournal - Sep 26 2014]
ACHILLION PHARMACEUTICALS : Patent Issued for N... [Published 4 Traders - Sep 25 2014]
Management of Hepatitis C Genotype 1 Monoinfection [Published General Medicine eJournal - Sep 24 2014]
NICE consults on draft guidance on the drug sim... [Published National AIDS Treatment Advocacy Project - Sep 23 2014]
Hepatitis C Therapeutics Market - Global Indust... [Published SBWire - Sep 23 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Opinion/decision on a Paediatric Investigation ... [Published Opinion/decision on a Paediatric Investigation ... - Sep 29 2014]
Sovaldi: Discontinuation, trends, and rationing [Published The Incidental Economist (Posts) - Sep 23 2014]
The following is a guest post by Allan Joseph, a medical student at the Warren Alpert Medical School of Brown University and TIE research assistant. You can follow Allan on Twitter: @allanmjoseph . You can read previous TIE coverage of Sovaldi here ...
The Hepatitis C virus is the main cause of live... [Published PR Newswire: General Business - Jul 25 2014]
PORT OF SPAIN, Trinidad and Tobago, July 25, 2014 /PRNewswire/ -- The Chemistry, Food & Drugs Division of the Trinidad & Tobago Ministry of Health approved the introduction of Telaprevir to the market, an innovative therapy that significantly increases ...
Treating Hepatitis C: Criticisms of sofosbuvir [Published The Incidental Economist (Posts) - Jun 17 2014]
The following is part of a series of guest posts on hepatitis C by Allan Joseph, a medical student at the Warren Alpert Medical School of Brown University and TIE research assistant. You can follow Allan on Twitter:  @allanmjoseph . Links to all posts ...
Treating Hepatitis C: Sofosbuvir [Published The Incidental Economist (Posts) - Jun 16 2014]
The following is part of a series of guest posts on hepatitis C by Allan Joseph, a medical student at the Warren Alpert Medical School of Brown University and TIE research assistant. You can follow Allan on Twitter:  @allanmjoseph . Links to all posts ...
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.